EVOLUS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
EVOLUS, INC. (EOLS) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $4.04 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $4.04M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $5.71M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.77M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.32M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $4.04M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.71M 10-Q · filed 2026-05-04 |
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $3.32M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $4.59M 10-Q · filed 2025-05-07 |
| 2024-09-30 | $1.02M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.91M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $2.93M 10-Q · filed 2024-05-07 |
| 2023-09-30 | $1.11M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.04M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.90M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $859.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.56M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $2.35M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $844.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.69M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $3.05M 10-Q · filed 2021-05-12 |
| 2020-09-30 | $1.71M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $3.17M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $4.63M 10-Q · filed 2020-05-11 |
| 2019-09-30 | $1.17M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $2.09M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $2.18M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |